Dissociative Disorders
Welcome,         Profile    Billing    Logout  
 5 Companies   7 Products   7 Products   7 Mechanisms of Action   0 Trials   89 News 


12»
  • ||||||||||  rasagiline / Generic mfg.
    Trial termination:  Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment (clinicaltrials.gov) -  Feb 20, 2019   
    P4,  N=23, Terminated, 
    Recruiting --> Completed | N=20 --> 26 Active, not recruiting --> Terminated; Persisting recruitment difficulties
  • ||||||||||  Enrollment change:  DOREFA (Retinal Detachment: Function and Anatomy) (clinicaltrials.gov) -  Dec 27, 2018   
    P=N/A,  N=202, Completed, 
    Active, not recruiting --> Terminated; Persisting recruitment difficulties N=120 --> 202
  • ||||||||||  Trial completion, Phase classification:  Treatment of Globus Sensations With Psychotherapy (clinicaltrials.gov) -  Oct 24, 2018   
    P=N/A,  N=175, Completed, 
    N=120 --> 202 Active, not recruiting --> Completed | Phase classification: P2/3 --> PN/A
  • ||||||||||  rasagiline / Generic mfg.
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment (clinicaltrials.gov) -  Aug 29, 2018   
    P4,  N=23, Active, not recruiting, 
    Active, not recruiting --> Completed | N=374 --> 224 Recruiting --> Active, not recruiting | N=40 --> 23 | Trial completion date: Dec 2020 --> Dec 2018 | Trial primary completion date: Dec 2020 --> Dec 2018
  • ||||||||||  Enrollment change, Trial completion date, Trial primary completion date:  Prognostic Value of Hemodynamic Disturbances in Rhegmatogenous Retinal Detachment (CRADO-RED) (clinicaltrials.gov) -  Feb 12, 2018   
    P=N/A,  N=41, Terminated, 
    Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Jul 2017 --> Jul 2018 N=150 --> 41 | Trial primary completion date: Jan 2018 --> Sep 2017 | Trial completion date: Jan 2018 --> Sep 2017
  • ||||||||||  Trial termination, Trial primary completion date:  Prognostic Value of Hemodynamic Disturbances in Rhegmatogenous Retinal Detachment (CRADO-RED) (clinicaltrials.gov) -  Feb 9, 2018   
    P=N/A,  N=150, Terminated, 
    N=150 --> 41 | Trial primary completion date: Jan 2018 --> Sep 2017 | Trial completion date: Jan 2018 --> Sep 2017 Recruiting --> Terminated | Trial primary completion date: Jan 2019 --> Jan 2018
  • ||||||||||  aripiprazole / Generic mfg., olanzapine / Generic mfg.
    Trial completion, Phase classification, Trial completion date, Trial primary completion date, Adverse events:  Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic (clinicaltrials.gov) -  Feb 5, 2018   
    P=N/A,  N=200, Completed, 
    Recruiting --> Terminated | Trial primary completion date: Jan 2019 --> Jan 2018 Active, not recruiting --> Completed | Phase classification: P4 --> PN/A | Trial primary completion date: May 2016 --> May 2017 | Trial completion date: Nov 2016 --> Jul 2017
  • ||||||||||  ursodeoxycholic acid / Generic mfg.
    Trial primary completion date:  UDCA-RD: Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment (clinicaltrials.gov) -  May 16, 2017   
    P1,  N=20, Recruiting, 
    Trial primary completion date: Jul 2018 --> Jan 2018 Trial primary completion date: Feb 2017 --> Aug 2017
  • ||||||||||  rasagiline / Generic mfg.
    Trial primary completion date:  Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment (clinicaltrials.gov) -  Jan 31, 2017   
    P4,  N=40, Recruiting, 
    Not yet recruiting --> Completed | N=48 --> 37 | Trial primary completion date: May 2017 --> Nov 2016 Trial primary completion date: Aug 2016 --> Dec 2020
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Trial completion, Enrollment change, Trial primary completion date:  Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments (clinicaltrials.gov) -  Jun 11, 2016   
    P4,  N=40, Completed, 
    Trial primary completion date: Jul 2016 --> Jul 2017 Active, not recruiting --> Completed | N=20 --> 40 | Trial primary completion date: Sep 2013 --> Dec 2014
  • ||||||||||  Trial completion:  Feasibility Study of Physiotherapy for Functional Motor Symptoms (clinicaltrials.gov) -  May 16, 2016   
    P=N/A,  N=60, Completed, 
    Active, not recruiting --> Completed | N=20 --> 40 | Trial primary completion date: Sep 2013 --> Dec 2014 Active, not recruiting --> Completed
  • ||||||||||  aripiprazole / Generic mfg., olanzapine / Generic mfg.
    Enrollment closed, Enrollment change, Trial primary completion date, Adverse events:  Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic (clinicaltrials.gov) -  Feb 10, 2016   
    P4,  N=200, Active, not recruiting, 
    Trial primary completion date: Jul 2015 --> Jul 2016 Recruiting --> Active, not recruiting | N=340 --> 200 | Trial primary completion date: Dec 2015 --> May 2016
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  TMS and Attentional Bias in Functional Motor Disorder (clinicaltrials.gov) -  Feb 9, 2016   
    P=N/A,  N=13, Completed, 
    Recruiting --> Active, not recruiting | N=340 --> 200 | Trial primary completion date: Dec 2015 --> May 2016 Recruiting --> Completed | N=40 --> 13 | Trial primary completion date: Aug 2015 --> Nov 2015
  • ||||||||||  Enrollment closed, Trial primary completion date:  Feasibility Study of Physiotherapy for Functional Motor Symptoms (clinicaltrials.gov) -  Oct 16, 2015   
    P=N/A,  N=60, Active, not recruiting, 
    Initiation date: Nov 2015 --> Mar 2016 | Trial primary completion date: May 2018 --> Sep 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Jan 2016
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Visudyne (verteporfin) / Novartis
    Enrollment change, Trial termination, Trial primary completion date:  A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes (clinicaltrials.gov) -  Sep 16, 2015   
    P=N/A,  N=9, Terminated, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Jan 2016 N=60 --> 9 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Sep 2015; treatment effects not as desired
  • ||||||||||  Enrollment closed:  Treatment of Globus Sensations With Psychotherapy (clinicaltrials.gov) -  Aug 12, 2015   
    P2/3,  N=175, Active, not recruiting, 
    N=10 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Treatment of Functional Movement Disorders With Psychotherapy (clinicaltrials.gov) -  Aug 11, 2015   
    P=N/A,  N=9, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed | N=70 --> 9 | Trial primary completion date: Apr 2016 --> Jul 2015
  • ||||||||||  Trial withdrawal:  Tissue Sectioning by Electro-Dissociation (clinicaltrials.gov) -  Mar 5, 2015   
    P=N/A,  N=0, Withdrawn, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Oct 2015 Terminated --> Withdrawn
  • ||||||||||  Enrollment change, Trial primary completion date:  Treatment of Globus Sensations With Psychotherapy (clinicaltrials.gov) -  Feb 11, 2015   
    P2/3,  N=175, Recruiting, 
    Terminated --> Withdrawn N=135 --> 175 | Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Enrollment open, Trial initiation date, Trial primary completion date:  TMS and Attentional Bias in Functional Motor Disorder (clinicaltrials.gov) -  Dec 17, 2014   
    P=N/A,  N=40, Recruiting, 
    N=135 --> 175 | Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Oct 2014 | Trial primary completion date: Oct 2014 --> Aug 2015